McKesson (NYSE:MCK – Get Free Report) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of $32.40-33.00 for the period, compared to the consensus EPS estimate of $32.68.
McKesson Stock Up 1.5 %
NYSE MCK opened at $594.11 on Wednesday. McKesson has a 12-month low of $464.42 and a 12-month high of $637.51. The firm’s 50 day moving average is $595.09 and its 200-day moving average is $560.90. The company has a market capitalization of $75.42 billion, a PE ratio of 30.77, a price-to-earnings-growth ratio of 1.25 and a beta of 0.52.
McKesson (NYSE:MCK – Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, topping the consensus estimate of $6.88 by $0.19. The firm had revenue of $93.65 billion for the quarter, compared to analysts’ expectations of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The company’s revenue for the quarter was up 21.3% on a year-over-year basis. During the same period in the previous year, the firm posted $6.23 EPS. As a group, sell-side analysts expect that McKesson will post 32.73 EPS for the current year.
McKesson Announces Dividend
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on the stock. Robert W. Baird raised shares of McKesson from a “neutral” rating to an “outperform” rating and raised their target price for the company from $531.00 to $688.00 in a research note on Thursday, November 7th. Wells Fargo & Company lifted their price objective on shares of McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a research report on Friday, December 13th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of McKesson from $623.00 to $579.00 and set a “buy” rating on the stock in a report on Wednesday, September 25th. Leerink Partners reduced their price target on McKesson from $665.00 to $630.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Finally, Bank of America dropped their price objective on McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Two investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, McKesson has a consensus rating of “Moderate Buy” and an average price target of $646.14.
View Our Latest Stock Report on MCK
Insider Activity
In other McKesson news, EVP Leann B. Smith sold 579 shares of McKesson stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $602.81, for a total value of $349,026.99. Following the completion of the sale, the executive vice president now owns 1,443 shares in the company, valued at $869,854.83. The trade was a 28.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.11% of the stock is currently owned by company insiders.
McKesson Company Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Featured Articles
- Five stocks we like better than McKesson
- What is MarketRankā¢? How to Use it
- 3 Dividend Stocks at Bargain Levels to Defend Your Portfolio
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 REITs With Big Dividend Growth and Sustainable Payouts
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Can Integrated Healthcare Stocks Succeed in Public Markets?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.